AQEMIA Reaches $100 Million in Funding, Plans Expansion and Prepares for Clinical Trials
AQEMIA, a techbio company teaching atomic scale physics to a generative AI, has announced reaching $100 million in cumulative funding. …
All Posts
Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor
Recursion (Nasdaq: RXRX) announced interim findings from the ongoing Phase 1/2 ELUCIDATE trial evaluating REC-617, a precision-designed, oral CDK7 inhibitor …
BioAge Labs Halts STRIDES Phase 2 Trial of Azelaprag-Tirzepatide Combo
BioAge Labs, which recently raised upwards of $198 million through an upsized IPO in September 2024 to fund its clinical …
Vittoria Biotherapeutics Highlights Novel CAR-T Cell Therapy Approach at ASH 2024
Vittoria Biotherapeutics, a Philadelphia-based clinical-stage immunotherapy company, showcased preclinical findings at the 66th Annual American Society of Hematology (ASH) Meeting.
Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer
Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its …
IDEAYA Demonstrates Preclinical Success with PRMT5 Inhibitor IDE892
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a clinical-stage precision medicine oncology company, announced the nomination of IDE892, a potent and selective …
Cherry Biotech Publishes Research on Advanced Skin-on-Chip Model in Microfluidics
Cherry Biotech has announced the publication of research on its CubiX platform in Advanced Healthcare Materials. The study explores a …
Antag Therapeutics Secures €80 Million to Advance GIPR-Based Obesity Therapies
Following the FDA’s October 2024 clearance of Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, the …
AI Proteins Announces Collaboration with Bristol Myers Squibb for Miniprotein Therapeutics Worth Up to $400 Million
AI Proteins, Inc., a biotechnology company specializing in the computational design of therapeutic miniproteins, announced a research collaboration and option …
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Rare Diseases and Oncology
Unnatural Products, Inc. a California-based biotech company specializing in AI-enabled massively parallel chemistry to develop orally bioavailable macrocyclic peptides, announced …
GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics from Sumitomo Chemical
GE HealthCare (NASDAQ: GEHC) announced an agreement to acquire Sumitomo Chemical’s 50% stake in Nihon Medi-Physics Co., Ltd. (NMP), assuming …
Recursion Begins First-in-Human Trial for AI-Discovered Protein Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
In October 2024, Recursion Pharmaceuticals received FDA clearance to initiate clinical trials for REC-1245, an investigational RBM39 degrader targeting biomarker-enriched …